HAART decreasing pneumonia incidence among children with HIV

Micheloud D. Pediatr Infect Dis J. 2012;doi:10.1097/INF.0b013e3182501cd4.

  • Infectious Diseases in Children, April 2012

The rate of pneumonia in children with HIV decreased due to highly active antiretroviral therapy, according to the results of a recent study.

Dariela Micheloud, MD, PhD, and colleagues of the Hospital General Universitario Gregorio Marañón in Madrid, Spain, performed a retrospective study on 168 children aged younger than 17 years with HIV who were hospitalized from 1997 to 2008.

Of 180 pneumonia diagnoses (some of the children were re-diagnosed), 137 had non-AIDS–defining pneumonia (non-ADP) and 43 had AIDS-defining pneumonia (ADP).

The researchers tracked disease patterns among the children and reported that the rate of pneumonia was four times higher in children with HIV than in the general population.

The overall rate of pneumonia (events per 1,000 HIV-infected children/year) in the whole follow-up period was 13.77. The non-ADP rate was 10.48 and ADP rate was 3.28, the researchers wrote.

Micheloud and colleagues attributed the reduced rate of ADP in children with HIV to increased use of HAART.

“The rate of pneumonia decreased among HIV-infected children in the HAART era, although the pneumonia rate still remains higher than in the general population,” the researchers said. “Non-ADP remains a significant health problem for HIV-infected children in Spain.”

The researchers noted some limitations to the data, notably lack of access to patient clinical data, data set anonymity and the lack of national coverage data of HIV-infected children in Spain.

Disclosure: The researchers report no relevant financial disclosures.

Perspective
Michael T. Brady, MD

Michael T. Brady

  • This manuscript highlights two important issues: 1) the impact of antiretroviral therapy to reduce infectious complications in HIV-1-infected children receiving treatment; and 2) Children with HIV-1-infection remain more vulnerable to infections than healthy uninfected children regardless of antiretroviral therapy.

    The authors acknowledge a number of limitations including an inability to assess compliance with antiretroviral regimens. The persistence in an increased risk for pneumonia in the treated HIV-1-infected children could be influenced by compliance and preservation of immune function. In addition, they do not provide information concerning whether the children (infected with HIV-1 or uninfected) received vaccines to prevent pneumococcal or Haemophilus influenzae type b infections. This would be relevant if these bacteria were more commonly noted in children with HIV-1 infection.

    The manuscript does not provide a description of the specific pathogens (viruses, bacteria, fungi, etc.) causing the AIDS-defining pneumonias nor the non-AIDS-defining pneumonias. The manuscript does not provide duration of hospitalization, intensive care admissions or any other measure of severity. The particular pathogens and severity of disease may be relevant to understanding the true increased burden of disease to antiretroviral-treated children with HIV-1 infection.

    Antiretroviral therapy has significantly improved the survival and quality of life of children with HIV-1 infection. This current manuscript documents a reduction in pneumonia hospitalizations during the time period when highly active antiretroviral therapy became available. It also notes that the rates of pneumonias continued to decline as one would anticipate greater utilization of antiretroviral therapy with opportunities for immune recovery. However, the persistent increase in the rate of pneumonias in the children with HIV-1 infection in this time period of antiretroviral therapy highlights the need to ensure access to HIV treatment, high rates of compliance with antiretroviral therapy and use of other important preventive interventions, such as appropriate immunizations and chemoprophylaxis for opportunistic infections if immune compromise exists.

    • Michael T. Brady , MD
    • Chair of the department of pediatrics, The Ohio State University/Nationwide Children’s Hospital, Columbus, Ohio
      Chair of the AAP’s Red Book Committee
  • Disclosures:Dr. Brady reports no relevant financial disclosures.

Comments

Healio is intended for health care provider use and all comments will be posted at the discretion of the editors. We reserve the right not to post any comments with unsolicited information about medical devices or other products. At no time will Healio be used for medical advice to patients.